Last reviewed · How we verify
Topical NSAID
Topical NSAIDs inhibit cyclooxygenase (COX) enzymes locally at the site of application to reduce prostaglandin synthesis and inflammation.
Topical NSAIDs inhibit cyclooxygenase (COX) enzymes locally at the site of application to reduce prostaglandin synthesis and inflammation. Used for Localized musculoskeletal pain and inflammation, Topical pain relief for arthritis and soft tissue injuries.
At a glance
| Generic name | Topical NSAID |
|---|---|
| Also known as | Ibuprofen 5% gel |
| Sponsor | University of Nottingham |
| Drug class | Nonsteroidal anti-inflammatory drug (NSAID) |
| Target | Cyclooxygenase (COX-1 and/or COX-2) |
| Modality | Small molecule |
| Therapeutic area | Pain management / Rheumatology / Dermatology |
| Phase | FDA-approved |
Mechanism of action
NSAIDs work by blocking COX-1 and/or COX-2 enzymes, which are responsible for producing prostaglandins that mediate pain, inflammation, and fever. When applied topically, the drug penetrates the skin and underlying tissues to provide localized anti-inflammatory and analgesic effects while minimizing systemic exposure. This approach reduces the risk of gastrointestinal and cardiovascular side effects associated with oral NSAIDs.
Approved indications
- Localized musculoskeletal pain and inflammation
- Topical pain relief for arthritis and soft tissue injuries
Common side effects
- Local skin irritation or erythema
- Contact dermatitis
- Photosensitivity
Key clinical trials
- Effects of Photobiomodulation and Topical Diclofenac on Inflammation and Pain in Knee Osteoarthritis (EPIC-KO) (PHASE2)
- Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt, Following Cataract Surgery (PHASE4)
- Human Cerebral Blood Flow Regulation (EARLY_PHASE1)
- Effects of 0.1% Nepafenac on Vitreous Inflammatory Biomarkers in Rhegmatogenous Retinal Detachment and Proliferative Vitreoretinopathy (PHASE4)
- Topical Diclofenac vs.Oral Ibuprofen for MSK Pain in Children (PHASE3)
- Comparing Post-intravitreal Injection Pain Scores Using Loteprednol, Bromfenac Sodium, and Artificial Tears Over a 24-hour Period (PHASE4)
- Effects of Bromfenac on Macular Thickness After Phacoemulsification Surgery (PHASE4)
- A Sequenced Strategy for Improving Outcomes in People With Knee Osteoarthritis Pain (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |